Interleukin-7 and immune reconstitution in cancer patients: a new paradigm for dramatically increasing overall survival; Morre M, Beq S. Target Oncol. 2012;7(1):55-68.
Interleukin-7 restores lymphocytes in septic shock: the IRIS-7 randomized clinical trial; Francois B, Jeannet R, Daix T, et al. JCI Insight. 2018;3(5):e98960. Published 2018 Mar 8.
Adjuvant Immunotherapy to Improve Outcome in High-Risk Pediatric Sarcomas; Merchant MS, Bernstein D, Amoako M, et al. Clin Cancer Res. 2016;22(13):3182-3191
Repeated Cycles of Recombinant Human Interleukin 7 in HIV-Infected Patients With Low CD4 T-Cell Reconstitution on Antiretroviral Therapy: Results of 2 Phase II Multicenter Studies; Thiébaut R, Jarne A, Routy JP, et al. Clin Infect Dis. 2016;62(9):1178-1185.
Effects of recombinant human interleukin 7 on T-cell recovery and thymic output in HIV-infected patients receiving antiretroviral therapy: results of a phase I/IIa randomized, placebo-controlled, multicenter study; Lévy Y, Sereti I, Tambussi G, et al. Clin Infect Dis. 2012;55(2):291-300.
IL-7 expands lymphocyte populations and enhances immune responses to sipuleucel-T in patients with metastatic castration-resistant prostate cancer (mCRPC); Pachynski RK, et al. J Immunother Cancer . 2021 Aug;9(8):e002903.
Interleukin-7 Reverses Lymphopenia and Improves T-cell Function in COVID-19 disease patient with inborn error of TLR3; Mazer MD, et al. Critical Care Explor. 2021; 3(7):e0500
IL-7 Immunotherapy in a Nonimmunocompromised Patient With Intractable Fungal Wound Sepsis; Turnbull IR, et al. Open Forum Infect Dis 2021 8(6): ofab256
Association of IL-7 Immunotherapy with Lymphocyte Counts in Patients with Severe COVID-19; Laterre PF, et al JAMA Network Open 2020;3(7): e2016485
Intravenously administered interleukin-7 to reverse lymphopenia in patients with septic shock: a double-blind, randomized, placebo-controlled trial. Daix T, Mathonnet A, Brakenridge S, et al. Ann Intensive Care. 2023;13(1):17. Published 2023 Mar 12.
